Aeglea Biotherapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Austin TX United States (2013)
Status: Acquired by Travere (2020)

Organization Overview

First Clinical Trial
2015
NCT02561234
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aeglea Biotherapeutics | Aeglea Biotherapeutics, Inc. | Aegle Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

pegylated arginine deiminase (5 trials)

Drugs in Phase 2 Trials (3)

acn00177 (1 trial)

agle 103 (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

agle-102 (1 trial)

co-argi-peg (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Hyperargininemia (Phase 3)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lung Neoplasms (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Preleukemia (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 6